Interacción paradójica entre nirmatrelvir/ritonavir y voriconazol en un paciente con COVID-19

This case is based on a drug interaction between nirmatrelvir/ritonavir (approved drug for COVID-19) and voriconazole is presented, possibly derived from the bidirectional effect of ritonavir on the 2 main voriconazole metabolising enzymes (cytochrome P450 3A and 2C19) ritonavir inhibits the former...

Descripción completa

Detalles Bibliográficos
Autores principales: Herranz Bayo, Elena, Merchante Andreu, Miriam, Huarte Lacunza, Rafael, Aguiló Lafarga, Irene, Abad Sazatornil, M. Reyes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U. 2023
Materias:
Caso Clínico
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805892/
https://www.ncbi.nlm.nih.gov/pubmed/36653282
http://dx.doi.org/10.1016/j.farma.2022.12.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805892/
https://www.ncbi.nlm.nih.gov/pubmed/36653282
http://dx.doi.org/10.1016/j.farma.2022.12.018

Ejemplares similares